Home · Guides · A plan for after

A plan for after

What happens when you stop tirzepatide with PMOS, and how to plan for it

The best time to plan for stopping is before your first dose. PMOS is a long condition, and the plan should be built for that.

Lantana editorial · Education only, not medical advice · Reviewed September 2026

Most conversations about tirzepatide are about starting. Far fewer are about what happens later, when the cost, the side effects, a pregnancy plan or simply time make you want to stop. For PCOS (PMOS), that second conversation matters more than usual, because the condition underneath does not end when the prescription does.

What the trial data show

The clearest evidence comes from a large trial called SURMOUNT-4, published in 2024. Adults with obesity or overweight took tirzepatide for 36 weeks and lost about 21% of their body weight on average. Then half were switched to a placebo and half continued. Over the following year, the group that stopped regained about 14% of their body weight, while the group that continued lost a further 5.5% or so.

That trial was not specific to PMOS, and it used the branded, FDA-approved product rather than a compounded one. But the direction is clear, and it matches what doctors see: for most people, stopping without a plan means much of the weight returns.

Why this matters more with PMOS

PMOS is usually driven by insulin resistance, and insulin resistance is a long-term trait rather than something a few months of treatment switches off. If weight and insulin sensitivity improved on treatment, and your cycles or androgen symptoms eased along with them, those benefits followed from the metabolic change. When the metabolic change reverses, it is reasonable to expect some of those downstream effects may too.

That is not a reason to stay on a medication forever. It is a reason to know, before you begin, what the program will do when you want to step down.

A starting dose is a prescription. A stopping plan is care.

What a good step-down plan covers

Questions to ask before you start

Ask these at the first appointment, not the last

That is the sixth of the Root Eight: a published plan for holding results and stepping down. It is one of the dimensions where providers differ most, and you can see each provider’s score in the full comparison.

Never stop or change a prescription without talking to the clinician managing it. GLP-1 medications are not FDA-approved to treat PCOS (PMOS). Compounded tirzepatide is not FDA-approved and is not reviewed by the FDA for safety or efficacy. Nothing here is medical advice.


See how providers score on a plan for after →